STOCK TITAN
  1. Home
  2. News
  3. DXR

Daxor Corp. - DXR STOCK NEWS

Welcome to our dedicated news page for Daxor (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Daxor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Daxor's position in the market.

News
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Rhea-AI Summary
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at the American College of Cardiology Scientific Sessions and published in the American Heart Journal showcase the value of BVA in improving outcomes and managing heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
News
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
Rhea-AI Summary
Daxor (Nasdaq: DXR) will exhibit at the MedAxiom CV Transforum Spring’24 Conference to showcase its blood volume diagnostic technology. The conference aims to transform cardiovascular care by providing education to industry leaders. Daxor's BVA diagnostic has shown significant improvements in patient outcomes, including mortality rates and readmissions, as well as reducing length of stay and healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
-
News
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
Rhea-AI Summary
Daxor announces the purchase of its BVA-100™ blood volume analyzer by a 450-bed teaching hospital in Chicago, aiming to improve patient outcomes and reduce healthcare costs. The company's sales are on the rise, with plans to secure contracts with two more hospitals in the area, showcasing positive growth and commercial success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
News
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Rhea-AI Summary
Daxor (DXR) to showcase blood volume measurement technology at ACC.24, aiming to enhance cardiovascular care through accurate data analysis. CEO Michael Feldschuh highlights the benefits of BVA technology in optimizing treatment plans and reducing healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
none
-
News
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
Rhea-AI Summary
Daxor (DXR) acquires exclusive rights and intellectual property for Volumex, Megatope, and Glofil from Iso-Tex Diagnostics, Inc. The acquisitions are expected to boost margins, increase revenue streams, and be cash flow positive immediately upon transfer of manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
acquisition
-
News
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
Rhea-AI Summary
Daxor (Nasdaq: DXR) to host an investor call on March 25, 2024, to review financial results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
earnings
News
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Rhea-AI Summary
Daxor (DXR) provided a corporate update highlighting significant progress in revenue growth, new customer acquisitions, and advancements in blood volume measurement technology. The company reported an increase in net asset value, successful clinical studies, new patents, and upcoming product launches. Daxor's focus on accurate blood volume measurement aims to improve patient outcomes and reduce healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
News
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
Rhea-AI Summary
Daxor (DXR) reports a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months of 2024 compared to the same period in 2023. The company's revenue increased by 31.8% in 2023 compared to 2022. The number of kits sold for their Diagnostic System rose by 36.2% in 2023. Daxor also launched 12 new accounts in 2023 and 6 new accounts in the first two months of 2024. The company anticipates breaking even within 12 months if FDA clearance for new units is obtained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
none
-
News
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) expands blood volume analysis (BVA) in three new hospitals through new analyzer purchases and ezBVA Lab service utilization. The new acquisitions drive BVA sales growth and highlight its clinical importance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.42%
Tags
none
News
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in heart failure patients with impaired renal function. The study showed the limitations of surrogate markers compared to Daxor's 98% accurate BVA system, emphasizing the importance of accurate blood volume measurement in optimizing therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Stock DXR logo
Daxor Corp.

Nasdaq:DXR

DXR Rankings

#4750 Ranked by Market Cap
#3989 Ranked by Stock Gains
N/A Ranked by Dividends

DXR Stock Data

45.92M
2.07M
57.09%
1.53%
0.14%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Oak Ridge

About DXR

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.